{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-032449","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.981461+00:00","generated_at":"2026-06-13T10:07:30.306677+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Adicet Bio appoints Katie Peng to Board; commercial launch experience from Denali, Genentech","bullets":["Katie Peng appointed to Board effective July 10, 2023; board size expanded from 8 to 9 directors.","Ms. Peng received option to purchase 70,200 shares at $3.38/share, vesting over 36 months.","She serves as Chief Commercial Officer at Denali Therapeutics, previously SVP at Genentech.","Led launches of OCREVUS (MS), Evrysdi (SMA), and HEMLIBRA (hemophilia A).","Appointment adds commercial expertise as Adicet advances ADI-001 towards pivotal study."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-032449","json":"https://secwatch.observer/filing/0000950170-23-032449.json","markdown":"https://secwatch.observer/filing/0000950170-23-032449.md","text":"https://secwatch.observer/filing/0000950170-23-032449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/0000950170-23-032449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/acet-20230710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:07:30.306677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"704cd1aa34","claim":"Katie Peng was appointed as Director at Adicet Bio, Inc..","evidence_excerpt":"the Board appointed Katie Peng to the Board, effective as of July 10, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/0000950170-23-032449-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}